Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

NCTID	NCT06018558 (View at clinicaltrials.gov)
Description	This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD). This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 63 subjects. (Show More)
Indication	Geographic Atrophy
Compound Name	OCU410
Sponsor	Ocugen
Funder Type	Industry
Status	Recruiting
Enrollment Count	63

Target Gene/Variant	RORA
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Overexpression of protective allele/gene
Route of Administration	Subretinal
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV5
Editor Type
Dose 1	2.5 x 10^10 vg/mL
Dose 2	5 x 10^10 vg/mL
Dose 3	1.5 x 10^11 vg/mL
Dose 4
Dose 5

No.of Trial Sites	9
Locations	United States

Has US IND	True
Recent Updates	Dosing of 3rd cohort completed July 2024